MKN-74 Xenograft Model Service for Gastric Cancer

The MKN-74 xenograft model offers a robust preclinical platform for evaluating gastric cancer therapeutics, leveraging a well-characterized moderately differentiated tubular adenocarcinoma cell line with documented tumorigenicity in immunocompromised hosts. At Alfa Cytology, we provide comprehensive, customizable MKN-74 xenograft model services designed to accelerate your preclinical drug development pipeline---from tumor implantation and compound administration to endpoint analysis and biomarker evaluation---ensuring high-quality, reproducible data that supports informed decision-making in gastric cancer research.

Overview of MKN-74 Xenograft Model for Gastric Cancer

MKN-74 is a human gastric cancer cell line originally established from a moderately differentiated tubular adenocarcinoma of the stomach in a 37-year-old Japanese male patient. As part of the well-known MKN series developed for gastric cancer research, MKN-74 cells exhibit epithelial morphology with intestinal differentiation features, including cell polarity and microvilli with core filaments. These characteristics are retained both in vitro and in xenograft settings, making the model highly representative of intestinal-type gastric adenocarcinoma. The cell line demonstrates anchorage-independent growth capacity, high proliferative potential, and documented tumorigenicity in nude mice, providing a reliable foundation for studying tumor progression, invasion, and metastatic mechanisms.

Molecularly, MKN-74 cells harbor alterations in key oncogenic and tumor suppressor pathways relevant to gastric cancer biology. They express synuclein gamma (SNCG), a gene associated with enhanced proliferation and metastatic capacity, and exhibit loss of RUNX3 mRNA expression. While typically possessing wild-type p53, some reports indicate the presence of a point mutation (I251L) in the TP53 gene. These molecular features, combined with the model's responsiveness to epidermal growth factor (EGF) signaling and DNA methylation dynamics, make the MKN-74 xenograft an invaluable tool for preclinical evaluation of targeted therapies, chemotherapy regimens, and novel drug candidates against gastric cancer.

Figure 1. Quantitative Analysis of In Vivo Proliferation of Different Cell Lines of Gastric Cancer. (Caia, Jing, et al., 2025)

Cell Line Information: MKN-74

The following table summarizes the essential characteristics and culture requirements of the MKN-74 cell line:

Our Services

Alfa Cytology is a specialized contract research organization dedicated to delivering high-quality preclinical tumor model services. With extensive experience in gastric cancer xenograft development, we offer end-to-end MKN-74 model solutions---including cell line authentication, tumor implantation, compound administration, tumor monitoring, and comprehensive endpoint analysis---tailored to meet your specific research objectives and accelerate your drug discovery programs.

Workflow of MKN-74 Xenograft Model Construction

The construction of the MKN-74 xenograft model follows a standardized, quality-controlled workflow that ensures reproducible tumor growth and reliable pharmacological readouts. Each stage is executed under IACUC-regulated, GLP-compliant conditions with rigorous documentation and quality assurance.

1. Step 1: Cell Line Authentication and Quality Control: MKN-74 cells are revived from cryopreserved stocks and expanded under standard culture conditions. Identity is confirmed via STR profiling, and cells are tested for mycoplasma contamination to ensure experimental integrity.
2. Step 2: Cell Harvesting and Preparation: Exponentially growing MKN-74 cells are harvested using enzymatic dissociation (trypsin-EDTA), washed with PBS, and resuspended in a serum-free medium or Matrigel mixture at optimal concentration (typically 5x10^6 to 1x10^7 cells per 100-200 microL).
3. Step 3: Animal Preparation and Implantation: Immunocompromised mice (e.g., athymic nude mice or NOD/SCID) are acclimatized and grouped according to body weight. MKN-74 cells are implanted subcutaneously into the flank region, or alternatively via orthotopic or intraperitoneal routes depending on study design.
4. Step 4: Tumor Establishment and Monitoring: Tumor growth is monitored twice weekly using caliper measurements. Tumor volume is calculated using the standard formula (length x width^2 / 2). Mice are randomized into treatment groups once tumors reach 100-200 mm^3.
5. Step 5: Test Compound Administration: Investigational compounds are administered according to the predefined dosing schedule via appropriate routes (intraperitoneal, intravenous, oral gavage, or subcutaneous). Vehicle controls and positive controls are included for comparative analysis.
6. Step 6: Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tumor growth inhibition (TGI) is calculated. Tissue samples are preserved via snap-freezing, RNAlater stabilization, or 10% NBF fixation for downstream histopathology, biomarker, and molecular analyses.

Figure 2: Schematic workflow illustrating the derivation and construction of the MKN-74 Xenograft Model at Alfa Cytology.

Case Study-MKN-74 Xenograft Model Development

In a representative preclinical study, MKN-74 xenografts were successfully established in athymic nude mice with a tumor take rate exceeding 90%. Tumors exhibited consistent growth kinetics with mean doubling times aligning with published in vitro data, and histological examination confirmed retention of moderately differentiated tubular adenocarcinoma morphology. Treatment with a reference compound resulted in dose-dependent tumor growth inhibition, validating the model's sensitivity to pharmacological intervention. Comprehensive endpoint analyses---including tumor volume measurements, body weight monitoring, and tissue histopathology---demonstrated the model's suitability for evaluating novel therapeutic candidates targeting gastric cancer proliferation and survival pathways. (Detailed quantitative data available upon request.)

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise with operational excellence to deliver reliable, high-quality MKN-74 xenograft model services that advance your preclinical research objectives.

• Extensive experience with gastric cancer cell line-based xenograft models, including the full MKN series.
• Rigorous cell line authentication via STR profiling and comprehensive mycoplasma testing for every study.
• Customizable study designs tailored to specific therapeutic modalities, dosing schedules, and endpoint requirements.
• IACUC-regulated, GLP-compliant vivarium facilities with SPF animals and controlled environmental conditions.
• Comprehensive data packages including tumor growth kinetics, body weight monitoring, histopathology, and biomarker analysis.
• Dedicated project management with regular progress updates and transparent communication throughout the study lifecycle.
• Strict confidentiality and full intellectual property protection for all client-sponsored research programs.

Contact Us

Ready to advance your gastric cancer preclinical research with our MKN-74 xenograft model service? Please reach out to us today via our inquiry form or email to learn more about our MKN-74 Xenograft Model services.

For research use only. Not intended for any clinical use.